Safety and ARIA Analyses of Oral Anti-amyloid Oligomer Agent Valiltramiprosate in APOE4/4 Homozygotes with Early Alzheimer’s Disease (AD): Results of the Phase 3 78-week APOLLOE4 Trial (S1.009)
Neurology · 2026-06-09
Cortical gray–white matter contrast alterations precede amyloid‐β positivity and macrostructural changes in older adults without dementia
Alzheimer s & Dementia · 2026-06-01
Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer’s Disease: Synthesis of Evidence from Observational and Interventional Trials
CNS Drugs · 2025-12-01 · 1 citations
Proteogenomics in cerebrospinal fluid and plasma reveals new biological fingerprint of cerebral small vessel disease
Nature Aging · 2025-11-20 · 2 citations
Associations of lifestyle factors with amyloid pathology in persons without dementia
Journal of Alzheimer s Disease · 2025-11-13
Psychometric Properties of the 7-Item Sense of Competence Questionnaire: Assessing Informal Caregivers’ Self-Perceived Competence in Mild Cognitive Impairment
Neurology and Therapy · 2025-11-08
A peripheral proteomic signature of Alzheimer’s disease is identified in the plasma extracellular vesicles of mild cognitive impairment patients from a memory clinic: the BIOPEXAL studyPreprint
Research Square · 2025-11-01
Sex-specific genetic regulation of proteomics in cerebrospinal fluid uncovers genetic causes for sex differences in neurodegenerationPreprint
medRxiv · 2025-10-31 · 2 citations
Cerebrospinal fluid proteomic signatures in cognitively normal individuals identify distinct clusters linked to neurodegeneration
Nature Aging · 2025-10-14 · 2 citations
Plasma Proteomic Signatures for Alzheimer's Disease: Comparable Accuracy to <scp>ATN</scp> Biomarkers and Cross‐Platform Validation
Annals of Clinical and Translational Neurology · 2025-10-13
Federated learning for cognitive impairment detection using speech data
Frontiers in Artificial Intelligence · 2025-10-09 · 1 citations
Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Aβ40 in patients with mild cognitive impairment or very mild Alzheimer's disease: A randomized, double‐blind, placebo‐controlled phase 2 study
Alzheimer s & Dementia · 2025-10-01 · 2 citations
Cortical thickness subtypes in cognitively unimpaired individuals: Differential network and transcriptomic vulnerability to cortical thinning
Alzheimer s & Dementia · 2025-10-01 · 2 citations
Lactoferrin levels in cerebrospinal fluid exhibits isoform-specific associations with Alzheimer’s diseasePreprint
medRxiv · 2025-09-30
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial
Drugs · 2025-09-28 · 15 citations
Cardiovascular health and cognition in older adults: Variations across recruitment models and European countries in the MOPEAD project
Journal of Alzheimer s Disease · 2025-09-03
Randomized phase 2a trial assessing a novel septin molecular glue in Alzheimer's disease
Alzheimer s & Dementia · 2025-09-01 · 7 citations
Harmonizing genotype array data to understand genetic risk for brain amyloid burden in the AMYPAD PNHS Consortium
Alzheimer s & Dementia · 2025-09-01 · 1 citations
Protein-based Diagnosis and Analysis of Co-pathologies Across Neurodegenerative Diseases: Large-Scale AI-Boosted CSF and Plasma ClassificationPreprint
Research Square · 2025-07-31
Cerebrospinal fluid biomarkers of Alzheimer's disease in Lewy body diseases: The performance of fully automated immunoassays
Journal of Alzheimer s Disease · 2025-07-27